Elimelech Rosner - Healthequity Ex CTO
2HE Stock | EUR 99.00 2.00 2.06% |
Insider
Elimelech Rosner is Ex CTO of Healthequity
Age | 66 |
Phone | 801 727 1000 |
Web | https://www.healthequity.com |
Elimelech Rosner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Elimelech Rosner against Healthequity stock is an integral part of due diligence when investing in Healthequity. Elimelech Rosner insider activity provides valuable insight into whether Healthequity is net buyers or sellers over its current business cycle. Note, Healthequity insiders must abide by specific rules, including filing SEC forms every time they buy or sell Healthequity'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Elimelech Rosner over two months ago Disposition of 12296 shares by Elimelech Rosner of HealthEquity at 77.0242 subject to Rule 16b-3 | ||
Elimelech Rosner over two months ago Disposition of 1727 shares by Elimelech Rosner of HealthEquity at 83.6769 subject to Rule 16b-3 | ||
Elimelech Rosner over two months ago Disposition of 12296 shares by Elimelech Rosner of HealthEquity at 77.0242 subject to Rule 16b-3 |
Healthequity Management Efficiency
Healthequity's management efficiency ratios could be used to measure how well Healthequity manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
David Bullock | Origin Agritech | 49 | |
Seth Frank | Evolent Health | N/A | |
Allison Miller | NMI Holdings | N/A | |
Amir Khoshniyati | Identiv | N/A | |
Patric Erlandsson | SIVERS SEMICONDUCTORS AB | 51 | |
Ash Rajendra | Superior Plus Corp | N/A | |
Caroline Schlienkamp | Talanx AG | 49 | |
Robert Green | SIVERS SEMICONDUCTORS AB | 60 | |
MAAA FSA | Evolent Health | 50 | |
Bjorn Norrbom | SIVERS SEMICONDUCTORS AB | 72 | |
Jan Wicke | Talanx AG | 55 | |
Geoffery Merszei | Origin Agritech | 68 | |
Mike Taylor | Identiv | N/A | |
CCLP CMA | Superior Plus Corp | 62 | |
JeanJacques Henchoz | Talanx AG | 59 | |
Wilm Langenbach | Talanx AG | 52 | |
Torsten Leue | Talanx AG | 57 | |
James Devens | Superior Plus Corp | N/A | |
Erik Fallstrom | SIVERS SEMICONDUCTORS AB | 56 | |
Steven Humphreys | Identiv | 62 | |
Christopher Lohmann | Talanx AG | 55 |
Management Performance
Return On Equity | -0.0313 | |||
Return On Asset | 0.0037 |
Healthequity Leadership Team
Elected by the shareholders, the Healthequity's board of directors comprises two types of representatives: Healthequity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Healthequity. The board's role is to monitor Healthequity's management team and ensure that shareholders' interests are well served. Healthequity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Healthequity's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jon Kessler, President CEO, Director | ||
Darcy Mott, CFO, Executive Vice President | ||
Delano Ladd, Executive Vice President General Counsel and Corporate Secretary | ||
Brad Bennion, Sr Devel | ||
Tyson Murdock, Ex CFO | ||
Elimelech Rosner, Ex CTO | ||
Tia Padia, VP Marketing | ||
Richard Putnam, IR Contact Officer | ||
Steve Lindsay, Ex Management | ||
Larry Trittschuh, Executive Vice President Chief Security Officer |
Healthequity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Healthequity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0313 | |||
Return On Asset | 0.0037 | |||
Profit Margin | (0.07) % | |||
Operating Margin | 0.02 % | |||
Current Valuation | 5.61 B | |||
Shares Outstanding | 84.64 M | |||
Shares Owned By Insiders | 1.96 % | |||
Shares Owned By Institutions | 98.04 % | |||
Price To Earning | 48.79 X | |||
Price To Book | 2.82 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Healthequity Stock
When determining whether Healthequity offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Healthequity's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Healthequity Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Healthequity Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Healthequity. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Healthequity Stock please use our How to Invest in Healthequity guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.